We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Toxic Protein Targets Cancer Cell COX-2 Synthesis

By Biotechdaily staff writers
Posted on 30 Jan 2003
A study exploring how cancer cells grow and spread has shown that the protein cytidine uridine guanosine binding protein-2 (CUGBP2) exerts a cytotoxic effect on cancer cells by interfering with the expression of cyclo-oxygenase-2 (COX-2). More...
The findings were reported in the January 17, 2003, issue of Molecular Cell.

Investigators from the Washington University School of Medicine (St. Louis, MO, USA) employed genetic engineering techniques to insert the gene for CUGPB2 into several different types of cancer cells growing in culture. They found that more than 70% of tumor cells could not survive when CUGBP2 was active. The target of CUGBP2 activity was shown to be the messenger RNA that coded for the production of COX-2. Significantly, CUGBP2 had no effect on normal cells.

"The gene that produces COX-2 is turned on very early in cancer, so there has been a lot of research to see whether interfering with it might be an effective therapy,” explained senior author Dr. Shrikant Anant, assistant professor of medicine in the Division of Gastroenterology at Washington University School of Medicine. "When CUGBP2 is introduced, there are a number of molecular derangements that take place in the cancer cell that make it susceptible to death. In the future, it may be possible to use this protein as a means of killing tumor cells without harming normal cells because normal cells already produce significant amounts of the protein.”




Related Links:
Washington Univ. School of Medicine

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.